000661 长春高新
已收盘 10-23 15:00:00
资讯
新帖
简况
10月23日长春高新涨5.40%，生物医药ETF国泰基金重仓该股
证券之星 · 10-23 16:44
10月23日长春高新涨5.40%，生物医药ETF国泰基金重仓该股
长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力
证券之星 · 10-20
长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力
长春高新：子公司GenSci155注射液临床试验申请获受理
同花顺 · 10-20
长春高新：子公司GenSci155注射液临床试验申请获受理
股市必读：长春高新新发布《关于子公司GenSci161注射液境内生产药品注册临床试验申请获得受理的公告》
证券之星 · 10-15
股市必读：长春高新新发布《关于子公司GenSci161注射液境内生产药品注册临床试验申请获得受理的公告》
长春高新最新公告：子公司GenSci161注射液临床试验申请获受理
证券之星 · 10-13
长春高新最新公告：子公司GenSci161注射液临床试验申请获受理
股市必读：长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划预留授予激励对象名单的核查意见及公示情况说明》
证券之星 · 10-13
股市必读：长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划预留授予激励对象名单的核查意见及公示情况说明》
长春高新：子公司甲磺酸亮丙瑞林注射液获药品注册证书
同花顺 · 10-09
长春高新：子公司甲磺酸亮丙瑞林注射液获药品注册证书
长春高新：第十一届董事会第二十三次会议决议公告
同花顺 · 10-07
长春高新：第十一届董事会第二十三次会议决议公告
长春高新(000661.SZ)下属子公司拟取得醋酸甲地孕酮口服混悬液相关权益
智通财经 · 10-07
长春高新(000661.SZ)下属子公司拟取得醋酸甲地孕酮口服混悬液相关权益
长春高新（000661）披露向2026年限制性股票激励计划激励对象授予预留限制性股票公告，9月30日股价上涨1.81%
证券之星 · 09-30
长春高新（000661）披露向2026年限制性股票激励计划激励对象授予预留限制性股票公告，9月30日股价上涨1.81%
长春高新：第十一届董事会第二十二次会议决议公告
同花顺 · 09-29
长春高新：第十一届董事会第二十二次会议决议公告
长春高新（000661）披露子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告，9月28日股价下跌0.49%
证券之星 · 09-28
长春高新（000661）披露子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告，9月28日股价下跌0.49%
长春高新最新公告：子公司伏欣奇拜单抗注射液临床试验申请获受理
证券之星 · 09-28
长春高新最新公告：子公司伏欣奇拜单抗注射液临床试验申请获受理
长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力
证券之星 · 09-24
长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力
长春高新：2026年半年度报告披露AI技术应用及在研管线进展
证券之星 · 09-24
长春高新：2026年半年度报告披露AI技术应用及在研管线进展
长春高新：公司经营层正在围绕既定战略目标全力推进各项业务开展
证券之星 · 09-24
长春高新：公司经营层正在围绕既定战略目标全力推进各项业务开展
长春高新：股权激励考核指标兼顾挑战性与可行性
证券之星 · 09-24
长春高新：股权激励考核指标兼顾挑战性与可行性
长春高新：销售费用主要用于销售人员薪酬及差旅、合规学术推广、医患科普、医院准入、渠道建设及新品市场培育
证券之星 · 09-24
长春高新：销售费用主要用于销售人员薪酬及差旅、合规学术推广、医患科普、医院准入、渠道建设及新品市场培育
长春高新（000661）披露子公司RSV单抗组合制剂临床试验申请获受理，9月22日股价下跌0.72%
证券之星 · 09-22
长春高新（000661）披露子公司RSV单抗组合制剂临床试验申请获受理，9月22日股价下跌0.72%
长春高新：公司以经营业绩为市值管理根本
证券之星 · 09-22
长春高新：公司以经营业绩为市值管理根本
暂无数据
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是生长激素系列产品、促卵泡激素系列、金蓓欣（伏欣奇拜单抗）、美适亚（醋酸甲地孕酮）、安脱达（屋尘螨变应原制剂）等。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":72.08,"timestamp":1792739001000,"preClose":68.39,"halted":0,"volume":6809732,"delay":0,"changeRate":0.054,"floatShares":395000000,"shares":408000000,"eps":-0.8643,"marketStatus":"已收盘","change":3.69,"latestTime":"10-23 15:00:00","open":68.49,"high":72.42,"low":67.87,"amount":479000000,"amplitude":0.0665,"askPrice":72.08,"askSize":2,"bidPrice":72.07,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-0.8643,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":68.39,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":75.23,"lowLimit":61.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.24,"roa":"--","roe":"2.14%","epsLYR":0.39,"committee":0.460722,"marketValue":29404000000,"turnoverRate":0.0172,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-26。","floatMarketCap":28456000000},"requestUrl":"/m/hq/s/000661/tweets","defaultTab":"tweets","newsList":[{"id":"2677944241","title":"10月23日长春高新涨5.40%，生物医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677944241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677944241?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:44","pubTimestamp":1792745052,"startTime":"0","endTime":"0","summary":"证券之星消息，10月23日长春高新涨5.40%创60日新低，收盘报72.08元，换手率1.72%，成交量6.81万手，成交额4.79亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为国泰基金的生物医药ETF国泰。生物医药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0028","BK0057","512290","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676695767","title":"长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2676695767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676695767?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:48","pubTimestamp":1792500497,"startTime":"0","endTime":"0","summary":"长春高新回复：您好，公司2026 年半年度报告中有AI技术应用的相关披露内容，具体如下：公司以AI技术创新为企业战略跃迁的核心驱动力，紧密围绕市场需求与临床应用价值，系统地将AI技术应用于研发、流程优化及企业级数字平台，以提升效率并支持创新，已在AI药物发现、大模型设计蛋白、临床研究设计等领域取得实质性突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0057","BK0239","BK0188","BK0075","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676664274","title":"长春高新：子公司GenSci155注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2676664274","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676664274?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:11","pubTimestamp":1792491060,"startTime":"0","endTime":"0","summary":"每经AI快讯，10月20日，长春高新(000661.SZ)公告称，公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》，GenSci155注射液境内生产药品注册临床试验申请获得受理。该药品为自主 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261020/c680893602.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261020/c680893602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["MDTX","BK0075","BK0239","IBBJ","BK0028","IBBQ","BK0188","000661","BMED","BK0057","PSYK","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675213403","title":"股市必读：长春高新新发布《关于子公司GenSci161注射液境内生产药品注册临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675213403","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675213403?lang=zh_cn&edition=full","pubTime":"2026-10-15 02:11","pubTimestamp":1792001469,"startTime":"0","endTime":"0","summary":"公司公告汇总关于子公司GenSci161注射液境内生产药品注册临床试验申请获得受理的公告长春高新控股子公司金赛药业收到国家药品监督管理局签发的《受理通知书》，其自主研发的GenSci161注射液用于复发性心包炎的境内生产药品注册临床试验申请已获受理。该药品为新型全人源单克隆IgG1双特异性抗体，可同时靶向IL-1α和IL-1β。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0239","BK0046","BK0028","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356530","title":"长春高新最新公告：子公司GenSci161注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356530","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675356530?lang=zh_cn&edition=full","pubTime":"2026-10-13 19:01","pubTimestamp":1791889283,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》，GenSci161注射液境内生产药品注册临床试验申请获受理，适应症为复发性心包炎。该药品为新型全人源单克隆IgG1双特异性抗体，可同时靶向IL-1α和IL-1β，抑制炎症反应。此前该药品用于子宫内膜异位症、化脓性汗腺炎等适应症的临床试验申请已获批准或受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300033067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0057","BK0188","BK0028","BK0046","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675289801","title":"股市必读：长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划预留授予激励对象名单的核查意见及公示情况说明》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675289801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675289801?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:10","pubTimestamp":1791825022,"startTime":"0","endTime":"0","summary":"公司公告汇总董事会薪酬与考核委员会关于2026年限制性股票激励计划预留授予激励对象名单的核查意见及公示情况说明长春高新董事会薪酬与考核委员会对公司2026年限制性股票激励计划预留授予激励对象名单的核查意见及公示情况进行说明。公示时间为2026年9月30日至10月9日，通过内部告示栏张贴，未收到异议。薪酬与考核委员会认为其主体资格合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0028","BK0188","BK0057","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674881552","title":"长春高新：子公司甲磺酸亮丙瑞林注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674881552","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674881552?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:03","pubTimestamp":1791507780,"startTime":"0","endTime":"0","summary":"中证智能财讯长春高新(000661)10月9日公告，公司控股子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药品注册证书》，其甲磺酸亮丙瑞林注射液(6M)的境外生产药品注册上 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261009/c680502762.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261009/c680502762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0057","BK0188","000661","BK0075","BK0028","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018105","title":"长春高新：第十一届董事会第二十三次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018105","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673018105?lang=zh_cn&edition=full","pubTime":"2026-10-07 20:23","pubTimestamp":1791375780,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月7日，长春高新发布公告称，公司于2026年9月30日召开第十一届董事会第二十三次会议，审议通过《关于金赛药业全资子公司拟取得醋酸甲地孕酮口 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261007/c680448560.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261007/c680448560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0075","000661","BK0028","BK0188","BK0057","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673976500","title":"长春高新(000661.SZ)下属子公司拟取得醋酸甲地孕酮口服混悬液相关权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2673976500","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673976500?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:06","pubTimestamp":1791371182,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新 发布公告，公司控股子公司金赛药业的全资子公司GENSCI Singapore与保盛药业拟签署《资产买卖合约》《供货合约》，保盛药业将其持有的醋酸甲地孕酮口服混悬液全球范围除匈牙利以外地区专属于该产品的知识产权及药品上市许可持有人权益转移给GENSCI Singapore，同时GENSCI Singapore授权委托保盛药业生产及长期供应该产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0046","BK0239","BK0057","BK0028","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671327096","title":"长春高新（000661）披露向2026年限制性股票激励计划激励对象授予预留限制性股票公告，9月30日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671327096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671327096?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:35","pubTimestamp":1790760924,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，长春高新报收于71.83元，较前一交易日上涨1.81%，最新总市值为293.02亿元。该股当日开盘70.56元，最高72.56元，最低70.21元，成交额达3.73亿元，换手率为1.31%。长春高新近日披露《关于向公司2026年限制性股票激励计划激励对象授予预留限制性股票的公告》。股票来源为公司从二级市场回购的A股股票，激励对象为控股子公司金赛药业核心管理、技术和业务骨干。本次授予满足激励计划规定的条件，公司及激励对象均未发生不得授予的情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000028077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0057","BK0239","BK0188","BK0075","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671217192","title":"长春高新：第十一届董事会第二十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2671217192","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671217192?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:23","pubTimestamp":1790688180,"startTime":"0","endTime":"0","summary":" 证券日报网讯 9月29日，长春高新发布公告称，公司于2026年9月29日召开第十一届董事会第二十二次会议，审议通过《关于向公司2026年限制性股票激励计划激励对象 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260929/c680379477.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260929/c680379477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0075","BK0046","BK0057","BK0188","BK0028","BK0239","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253064","title":"长春高新（000661）披露子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告，9月28日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670253064?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:19","pubTimestamp":1790605156,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，长春高新报收于70.5元，较前一交易日下跌0.49%，最新总市值为287.6亿元。近日，长春高新技术产业（集团）股份有限公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其注射用GenSci136境内生产药品注册临床试验申请获得批准，拟用于治疗系统性红斑狼疮。该药此前已获准开展针对全身型重症肌无力、免疫球蛋白A肾病等适应症的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0188","BK0046","BK0028","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236302","title":"长春高新最新公告：子公司伏欣奇拜单抗注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236302","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670236302?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:11","pubTimestamp":1790590261,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司子公司金赛药业收到国家药品监督管理局《受理通知书》，伏欣奇拜单抗注射液境内生产药品注册临床试验申请获受理，拟用于治疗结缔组织病相关间质性肺疾病(CTD-ILD)。该药品为全人源抗白介素-1β单抗，目前尚无药物获批用于所有CTD-ILD人群，临床需求较大。此前该药品用于急性痛风性关节炎适应症已获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800024470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0028","BK0075","BK0188","BK0046","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669980634","title":"长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2669980634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669980634?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:51","pubTimestamp":1790254272,"startTime":"0","endTime":"0","summary":"长春高新回复：您好，公司2026 年半年度报告中有相关披露内容，具体如下：公司以AI技术创新为企业战略跃迁的核心驱动力，紧密围绕市场需求与临床应用价值，系统地将AI技术应用于研发、流程优化及企业级数字平台，以提升效率并支持创新，已在AI药物发现、大模型设计蛋白、临床研究设计等领域取得实质性突破。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400038282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0028","BK0057","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715498","title":"长春高新：2026年半年度报告披露AI技术应用及在研管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715498","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669715498?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:48","pubTimestamp":1790254091,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新09月23日在投资者关系平台上答复投资者关心的问题。请问公司所说多措并举稳定市值，除了常规做好经营外，有没有回购注销、加大AI制药管线信息披露这类实质性行动？本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400038155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0028","BK0075","BK0188","BK0239","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669790455","title":"长春高新：公司经营层正在围绕既定战略目标全力推进各项业务开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2669790455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669790455?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:33","pubTimestamp":1790220799,"startTime":"0","endTime":"0","summary":"投资者关心的市值管理问题一直未得到解决，股价连续6年下跌，利润也在缩水；另公司销售费用居高不下，但利润回报和销售费用严重倒挂的问题，一直未得到解决长春高新回复：您好，公司经营层正在围绕既定战略目标全力推进各项业务开展，努力实现激励计划设定的考核要求；公司 BD 业务围绕既定战略持续推进，如后续有正式合作协议，公司将严格按照法律法规要求及时履行信息披露义务，具体请以公司公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0239","BK0046","BK0057","BK0075","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669455726","title":"长春高新：股权激励考核指标兼顾挑战性与可行性","url":"https://stock-news.laohu8.com/highlight/detail?id=2669455726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669455726?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:33","pubTimestamp":1790220799,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新09月24日在投资者关系平台上答复投资者关心的问题。当前业绩持续走弱的背景下，管理层仍实施股权激励，相关考核指标设置过低。考核门槛设置如此宽松，业绩一年不如一年仍可达成激励条件，如何保障中小股东权益？股权激励使用的是上市公司全体股东的资源，在经营表现持续低迷时实施激励，管理层如何说明该方案的合理性？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0239","BK0057","BK0028","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669557184","title":"长春高新：销售费用主要用于销售人员薪酬及差旅、合规学术推广、医患科普、医院准入、渠道建设及新品市场培育","url":"https://stock-news.laohu8.com/highlight/detail?id=2669557184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669557184?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:33","pubTimestamp":1790220797,"startTime":"0","endTime":"0","summary":"核心生长激素已经进医保，本不需要大量推广，公司销售费用远高于安科生物、特宝生物，但是高额销售费用投入，销售额却没有增长。生长激素医保覆盖适应症有限，多数患者自费；作为处方药，仍需持续开展合规学术推广等；同时公司创新产品上市，需要前期市场投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","000661","BK0075","BK0028","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669812833","title":"长春高新（000661）披露子公司RSV单抗组合制剂临床试验申请获受理，9月22日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669812833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669812833?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:20","pubTimestamp":1790086828,"startTime":"0","endTime":"0","summary":"近日，长春高新技术产业（集团）股份有限公司子公司长春百克生物科技股份公司收到国家药品监督管理局下发的重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请的《受理通知书》，受理号为CXSL2601038。该产品用于预防新生儿和婴幼儿由RSV引起的下呼吸道感染，具有良好的药效和安全性，可实现单次给药覆盖一个RSV流行季。目前国内已上市4款RSV抗体，均为单价产品，而百克生物申报的产品为鸡尾酒组合制剂，具有更强的中和活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200041770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0188","BK0028","BK0239","BK0057","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669116411","title":"长春高新：公司以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669116411?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:06","pubTimestamp":1790060784,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新09月22日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200020763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0028","BK0188","BK0057","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792836785554,"stockEarnings":[{"period":"1week","weight":0.0538},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.1542},{"period":"1year","weight":-0.3861},{"period":"ytd","weight":-0.2196}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"130136人(较上一季度减少5.79%)","perCapita":"3030股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是生长激素系列产品、促卵泡激素系列、金蓓欣（伏欣奇拜单抗）、美适亚（醋酸甲地孕酮）、安脱达（屋尘螨变应原制剂）等。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}